{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:46:52Z","timestamp":1789051612043,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81"],"award-info":[{"award-number":["81"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["972"],"award-info":[{"award-number":["972"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["728"],"award-info":[{"award-number":["728"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40291-024-00746-6","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T16:01:44Z","timestamp":1727452904000},"page":"81-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Diagnostic Utility of a 90-Gene Expression Assay (Canhelp-Origin) for Patients with Metastatic Cancer with an Unclear or Unknown Diagnosis"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5048-9604","authenticated-orcid":false,"given":"Peng","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"issue":"19","key":"746_CR1","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1001\/archinte.1995.00430190036005","volume":"155","author":"DV Schapira","year":"1995","unstructured":"Schapira DV, Jarrett AR. The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma. Arch Intern Med. 1995;155(19):2050\u20134.","journal-title":"Arch Intern Med"},{"issue":"7","key":"746_CR2","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ctrv.2015.05.010","volume":"41","author":"P Economopoulou","year":"2015","unstructured":"Economopoulou P, Mountzios G, Pavlidis N, Pentheroudakis G. Cancer of unknown primary origin in the genomic era: elucidating the dark box of cancer. Cancer Treat Rev. 2015;41(7):598\u2013604. https:\/\/doi.org\/10.1016\/j.ctrv.2015.05.010.","journal-title":"Cancer Treat Rev"},{"issue":"14","key":"746_CR3","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.3390\/cancers14143429","volume":"14","author":"P Krawczyk","year":"2022","unstructured":"Krawczyk P, Jassem J, Wojas-Krawczyk K, Krzakowski M, Dziadziuszko R, Olszewski W. New genetic technologies in diagnosis and treatment of cancer of unknown primary. Cancers. 2022;14(14):3429. https:\/\/doi.org\/10.3390\/cancers14143429.","journal-title":"Cancers"},{"issue":"4","key":"746_CR4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/cancers10040108","volume":"10","author":"J Selves","year":"2018","unstructured":"Selves J, Long-Mira E, Mathieu MC, Rochaix P, Ili\u00e9 M. Immunohistochemistry for diagnosis of metastatic carcinomas of unknown primary site. Cancers. 2018;10(4):108. https:\/\/doi.org\/10.3390\/cancers10040108.","journal-title":"Cancers"},{"issue":"1","key":"746_CR5","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41467-024-47195-7","volume":"15","author":"AM Conway","year":"2024","unstructured":"Conway AM, Pearce SP, Clipson A, et al. A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary. Nat Commun. 2024;15(1):3292. https:\/\/doi.org\/10.1038\/s41467-024-47195-7.","journal-title":"Nat Commun"},{"key":"746_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejca.2021.09.031","volume":"159","author":"S Woo","year":"2021","unstructured":"Woo S, Becker AS, Do RKG, Sch\u00f6der H, Hricak H, Alberto VH. Impact of 18F-Fluorodeoxyglucose positron emission tomography on management of cancer of unknown primary: systematic review and meta-analysis. Eur J Cancer. 2021;159:60\u201377. https:\/\/doi.org\/10.1016\/j.ejca.2021.09.031.","journal-title":"Eur J Cancer"},{"issue":"2","key":"746_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbae028","volume":"25","author":"W Ma","year":"2024","unstructured":"Ma W, Wu H, Chen Y, et al. New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges. Brief Bioinform. 2024;25(2): bbae028. https:\/\/doi.org\/10.1093\/bib\/bbae028.","journal-title":"Brief Bioinform"},{"issue":"1","key":"746_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/jamaoncol.2019.3985","volume":"6","author":"A Penson","year":"2020","unstructured":"Penson A, Camacho N, Zheng Y, et al. Development of genome-derived tumor type prediction to inform clinical cancer care. JAMA Oncol. 2020;6(1):84. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3985.","journal-title":"JAMA Oncol"},{"issue":"9","key":"746_CR9","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.jmoldx.2020.06.005","volume":"22","author":"Q Ye","year":"2020","unstructured":"Ye Q, Wang Q, Qi P, et al. Development and clinical validation of a 90-gene expression assay for identifying tumor tissue origin. J Mol Diagn. 2020;22(9):1139\u201350. https:\/\/doi.org\/10.1016\/j.jmoldx.2020.06.005.","journal-title":"J Mol Diagn"},{"issue":"6","key":"746_CR10","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"MC Liu","year":"2020","unstructured":"Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745\u201359. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.011.","journal-title":"Ann Oncol"},{"issue":"1","key":"746_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12967-022-03318-6","volume":"20","author":"W Sun","year":"2022","unstructured":"Sun W, Wu W, Wang Q, et al. Clinical validation of a 90-gene expression test for tumor tissue of origin diagnosis: a large-scale multicenter study of 1417 patients. J Transl Med. 2022;20(1):114. https:\/\/doi.org\/10.1186\/s12967-022-03318-6.","journal-title":"J Transl Med"},{"issue":"8","key":"746_CR12","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/S1470-2045(24)00313-9","volume":"25","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang X, Jiang S, et al. Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial. Lancet Oncol. 2024;25(8):1092\u2013102. https:\/\/doi.org\/10.1016\/S1470-2045(24)00313-9.","journal-title":"Lancet Oncol"},{"issue":"3","key":"746_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.annonc.2022.11.013","volume":"34","author":"A Kr\u00e4mer","year":"2023","unstructured":"Kr\u00e4mer A, Bochtler T, Pauli C, et al. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(3):228\u201346. https:\/\/doi.org\/10.1016\/j.annonc.2022.11.013.","journal-title":"Ann Oncol"},{"issue":"8","key":"746_CR14","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMoa1502309","volume":"373","author":"DM Hyman","year":"2015","unstructured":"Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1502309.","journal-title":"N Engl J Med"},{"issue":"34","key":"746_CR15","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","volume":"33","author":"S Kopetz","year":"2015","unstructured":"Kopetz S, Desai J, Chan E, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF -mutated colorectal cancer. J Clin Oncol. 2015;33(34):4032\u20138. https:\/\/doi.org\/10.1200\/JCO.2015.63.2497.","journal-title":"J Clin Oncol"},{"issue":"6","key":"746_CR16","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","volume":"36","author":"JD Hainsworth","year":"2018","unstructured":"Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from mypathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018;36(6):536\u201342. https:\/\/doi.org\/10.1200\/JCO.2017.75.3780.","journal-title":"J Clin Oncol"},{"issue":"10","key":"746_CR17","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1200\/JCO.2008.20.0600","volume":"27","author":"MT Lee","year":"2009","unstructured":"Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27(10):1585\u201391. https:\/\/doi.org\/10.1200\/JCO.2008.20.0600.","journal-title":"J Clin Oncol"},{"issue":"3","key":"746_CR18","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ijrobp.2011.08.036","volume":"83","author":"MT Milano","year":"2012","unstructured":"Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol. 2012;83(3):878\u201386. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.08.036.","journal-title":"Int J Radiat Oncol"},{"issue":"5","key":"746_CR19","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ijrobp.2016.03.050","volume":"95","author":"KA Ahmed","year":"2016","unstructured":"Ahmed KA, Caudell JJ, El-Haddad G, et al. Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy. Int J Radiat Oncol. 2016;95(5):1399\u2013404. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.03.050.","journal-title":"Int J Radiat Oncol"},{"issue":"2","key":"746_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","volume":"31","author":"JD Hainsworth","year":"2013","unstructured":"Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah cannon research institute. J Clin Oncol. 2013;31(2):217\u201323. https:\/\/doi.org\/10.1200\/JCO.2012.43.3755.","journal-title":"J Clin Oncol"},{"issue":"15","key":"746_CR21","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1200\/JCO.2008.17.9762","volume":"27","author":"FA Monzon","year":"2009","unstructured":"Monzon FA, Lyons-Weiler M, Buturovic LJ, et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol. 2009;27(15):2503\u20138. https:\/\/doi.org\/10.1200\/JCO.2008.17.9762.","journal-title":"J Clin Oncol"},{"issue":"14","key":"746_CR22","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1158\/1078-0432.CCR-12-0920","volume":"18","author":"SE Kerr","year":"2012","unstructured":"Kerr SE, Schnabel CA, Sullivan PS, et al. Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. Clin Cancer Res. 2012;18(14):3952\u201360. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0920.","journal-title":"Clin Cancer Res"},{"key":"746_CR23","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3389\/fonc.2019.00354","volume":"9","author":"Q Wang","year":"2019","unstructured":"Wang Q, Xu M, Sun Y, et al. Gene expression profiling for diagnosis of triple-negative breast cancer: a multicentre, retrospective cohort study. Front Oncol. 2019;9:354. https:\/\/doi.org\/10.3389\/fonc.2019.00354.","journal-title":"Front Oncol"},{"issue":"1","key":"746_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12967-019-2082-1","volume":"17","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Ding Y, Wang Q, et al. 90-gene signature assay for tissue origin diagnosis of brain metastases. J Transl Med. 2019;17(1):331. https:\/\/doi.org\/10.1186\/s12967-019-2082-1.","journal-title":"J Transl Med"},{"issue":"2","key":"746_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/abbs\/gmz153","volume":"52","author":"N Qu","year":"2020","unstructured":"Qu N, Huang D, Xu Q, et al. Gene expression profiling of cells of origin of squamous cell carcinomas in head-and-neck, esophagus, and lung. Acta Biochim Biophys Sin. 2020;52(2):211\u20134. https:\/\/doi.org\/10.1093\/abbs\/gmz153.","journal-title":"Acta Biochim Biophys Sin"},{"issue":"1","key":"746_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12935-021-01748-8","volume":"21","author":"Y Zheng","year":"2021","unstructured":"Zheng Y, Sun Y, Kuai Y, et al. Gene expression profiling for the diagnosis of multiple primary malignant tumors. Cancer Cell Int. 2021;21(1):47. https:\/\/doi.org\/10.1186\/s12935-021-01748-8.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"746_CR27","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1186\/s12885-023-11563-1","volume":"23","author":"M Ren","year":"2023","unstructured":"Ren M, Cai X, Jia L, et al. Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China. BMC Cancer. 2023;23(1):1175. https:\/\/doi.org\/10.1186\/s12885-023-11563-1.","journal-title":"BMC Cancer"},{"issue":"7","key":"746_CR28","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1097\/PAS.0b013e31828309c4","volume":"37","author":"CR Handorf","year":"2013","unstructured":"Handorf CR, Kulkarni A, Grenert JP, et al. A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors. Am J Surg Pathol. 2013;37(7):1067\u201375. https:\/\/doi.org\/10.1097\/PAS.0b013e31828309c4.","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"746_CR29","doi-asserted-by":"publisher","first-page":"620","DOI":"10.18632\/oncotarget.521","volume":"3","author":"JS Nystrom","year":"2012","unstructured":"Nystrom JS, Hornberger JC, Varadhachary GR, et al. Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival. Oncotarget. 2012;3(6):620\u20138. https:\/\/doi.org\/10.18632\/oncotarget.521.","journal-title":"Oncotarget"},{"issue":"12","key":"746_CR30","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/jjco\/hyac143","volume":"52","author":"K Nishikawa","year":"2022","unstructured":"Nishikawa K, Hironaka S, Inagaki T, et al. A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site. Jpn J Clin Oncol. 2022;52(12):1416\u201322. https:\/\/doi.org\/10.1093\/jjco\/hyac143.","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"746_CR31","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/cam4.4973","volume":"12","author":"P Qi","year":"2023","unstructured":"Qi P, Sun Y, Liu X, et al. Clinicopathological, molecular and prognostic characteristics of cancer of unknown primary in China: an analysis of 1420 cases. Cancer Med. 2023;12(2):1177\u201388. https:\/\/doi.org\/10.1002\/cam4.4973.","journal-title":"Cancer Med"},{"issue":"9","key":"746_CR32","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1002\/cam4.1689","volume":"7","author":"C Binder","year":"2018","unstructured":"Binder C, Matthes KL, Korol D, Rohrmann S, Moch H. Cancer of unknown primary\u2014epidemiological trends and relevance of comprehensive genomic profiling. Cancer Med. 2018;7(9):4814\u201324. https:\/\/doi.org\/10.1002\/cam4.1689.","journal-title":"Cancer Med"},{"key":"746_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102204","volume":"97","author":"T Olivier","year":"2021","unstructured":"Olivier T, Fernandez E, Labidi-Galy I, et al. Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm? Cancer Treat Rev. 2021;97: 102204. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102204.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"746_CR34","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1080\/02841860701243095","volume":"46","author":"N Pavlidis","year":"2007","unstructured":"Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol. 2007;46(5):592\u2013601. https:\/\/doi.org\/10.1080\/02841860701243095.","journal-title":"Acta Oncol"},{"issue":"1","key":"746_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1479-5876-10-12","volume":"10","author":"GM Stella","year":"2012","unstructured":"Stella GM, Senetta R, Cassenti A, Ronco M, Cassoni P. Cancers of unknown primary origin: current perspectives and future therapeutic strategies. J Transl Med. 2012;10(1):12. https:\/\/doi.org\/10.1186\/1479-5876-10-12.","journal-title":"J Transl Med"},{"issue":"7","key":"746_CR36","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.18.00771","volume":"37","author":"H Hayashi","year":"2019","unstructured":"Hayashi H, Kurata T, Takiguchi Y, et al. Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site. J Clin Oncol. 2019;37(7):570\u20139. https:\/\/doi.org\/10.1200\/JCO.18.00771.","journal-title":"J Clin Oncol"},{"key":"746_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz394","volume":"30","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Maillard A, Penel N, et al. LBA15_PR\u2014a phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04). Ann Oncol. 2019;30: v851. https:\/\/doi.org\/10.1093\/annonc\/mdz394.","journal-title":"Ann Oncol"},{"issue":"10","key":"746_CR38","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","volume":"17","author":"S Moran","year":"2016","unstructured":"Moran S, Mart\u00ednez-Card\u00fas A, Sayols S, et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol. 2016;17(10):1386\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(16)30297-2.","journal-title":"Lancet Oncol"},{"key":"746_CR39","unstructured":"Treatment by Cancer Type. NCCN. Accessed July 3, 2024. https:\/\/www.nccn.org\/guidelines\/category_1"},{"issue":"6","key":"746_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7052","volume":"13","author":"EL Boys","year":"2024","unstructured":"Boys EL, Gao B, Grimison P, et al. Retrospective analysis of clinical characteristics and outcomes of patients with carcinoma of unknown primary from three tertiary centers in Australia. Cancer Med. 2024;13(6): e7052. https:\/\/doi.org\/10.1002\/cam4.7052.","journal-title":"Cancer Med"},{"issue":"2","key":"746_CR41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41416-023-02254-6","volume":"129","author":"A van Mourik","year":"2023","unstructured":"van Mourik A, Tonkin-Hill G, O\u2019Farrell J, et al. Six-year experience of Australia\u2019s first dedicated cancer of unknown primary clinic. Br J Cancer. 2023;129(2):301\u20138. https:\/\/doi.org\/10.1038\/s41416-023-02254-6.","journal-title":"Br J Cancer"},{"issue":"3","key":"746_CR42","doi-asserted-by":"publisher","first-page":"244","DOI":"10.20517\/evcna.2022.20","volume":"3","author":"RH Eibl","year":"2022","unstructured":"Eibl RH, Schneemann M. Cell-free DNA as a biomarker in cancer. Extracell Vesicles Circ Nucl Acids. 2022;3(3):244\u20138. https:\/\/doi.org\/10.20517\/evcna.2022.20.","journal-title":"Extracell Vesicles Circ Nucl Acids"},{"issue":"3","key":"746_CR43","doi-asserted-by":"publisher","first-page":"461","DOI":"10.20517\/evcna.2023.37","volume":"4","author":"T Asao","year":"2023","unstructured":"Asao T, Tobias GC, Lucotti S, et al. Extracellular vesicles and particles as mediators of long-range communication in cancer: connecting biological function to clinical applications. Extracell Vesicles Circ Nucl Acids. 2023;4(3):461\u201385. https:\/\/doi.org\/10.20517\/evcna.2023.37.","journal-title":"Extracell Vesicles Circ Nucl Acids"},{"issue":"4","key":"746_CR44","doi-asserted-by":"publisher","first-page":"403","DOI":"10.19401\/j.cnki.1007-3639.2023.04.011","volume":"33","author":"Society of Cancer of Multiple and Unknown Primary of China Anti-Cancer Association Yuguang","year":"2023","unstructured":"Society of Cancer of Multiple and Unknown Primary of China Anti-Cancer Association Yuguang. China Anti-Cancer Association guideline for diagnosis and treatment of cancer of multiple and unknown primaries (2023 edition). China Oncol. 2023;33(4):403\u201322. https:\/\/doi.org\/10.19401\/j.cnki.1007-3639.2023.04.011.","journal-title":"China Oncol."}],"container-title":["Molecular Diagnosis &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00746-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-024-00746-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00746-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T07:48:21Z","timestamp":1737100101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-024-00746-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["746"],"URL":"https:\/\/doi.org\/10.1007\/s40291-024-00746-6","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"15 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent to participate in the study were obtained from the Clinical Research Ethics Committee of Fudan University Shanghai Cancer Center (FUSCC, Shanghai, China).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data generated or analyzed during this study are included in this published article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Authors Yifeng Sun and Qinghua Xu were employed of the company Canhelp Genomics Co., Ltd. The remaining authors, Peng Qi, Yue Pang, Jing Liu, Xu Cai, Shenglin Huang, Qifeng Wang, and Xiaoyan Zhou, declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This work was supported by research funding from the National Natural Science Foundation of China grants 81,972,728 and 82,272,626, the Innovation Group Project of Shanghai Municipal Health Commission (No. 2019CXJQ03), the Shanghai Science and Technology Development Foundation (No. 19MC1911000), the Shanghai Municipal Key Clinical Specialty (No. shslczdzk01301), the Innovation Program of Shanghai Science and Technology Committee (No. 20Z11900300), and the Clinical Research Plan of Shanghai Hospital Development Center (No. SHDC2020CR3046B).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"P. Q. and X.Y. Z. designed the study. Q.F. W. and X. C. provided the specimens and collected clinical information. P. Q., Y.F. S., Y. P., J. L., S.L. H., and Q.H. X. performed the experiments and analyzed all data. P. Q. and Y.F. S. wrote the initial manuscript draft. Q.H. X., Q.F. W., and X.Y. Z. critically revised the manuscript and gave valuable insight into the study concept. All authors revised the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions Statement"}}]}}